CAR Chase: Where Do Engineered Cells Go in Humans?

Area of Science:

• Immunotherapy
• Molecular Imaging
• Oncology

Background:

• Engineered T-cells, including chimeric antigen receptor (CAR) and T-cell receptor (TCR) modified T-cells, show promise for cancer treatment but have variable responses and toxicities.
• Current methods for tracking T-cells lack spatiotemporal information, hindering understanding of treatment efficacy and failure modes, especially in solid tumors.
• Predicting therapeutic outcomes and adverse events for engineered T-cell therapies remains a significant challenge.

Purpose of the Study:

• To propose reporter gene-based imaging as a valuable tool for elucidating the fate of engineered T-cells in vivo.
• To facilitate the clinical translation of novel CAR and TCR technologies by improving T-cell tracking.
• To outline current reporter gene approaches, analyze limitations, and propose design principles for human applications.

Main Methods:

• Review of current reporter gene strategies for tracking engineered cells in vivo.
• Analysis of reasons why existing reporter genes have not advanced to clinical use.
• Development of proposed design 'rules' for a widely applicable human reporter gene.

Main Results:

• Current reporter gene technologies face challenges in progressing to human clinical trials.
• Significant knowledge gaps exist regarding the pharmacokinetics and biodistribution of infused engineered T-cells.
• The study lays the groundwork for designing effective reporter genes for clinical T-cell tracking.

Conclusions:

• Reporter gene-based imaging offers a promising avenue to overcome current limitations in engineered T-cell therapy.
• Establishing clear design principles is crucial for developing reporter genes suitable for human application.
• Successful implementation of reporter gene imaging could significantly enhance the safety and efficacy of T-cell-based cancer treatments.